Abstract Sacubitril/valsartan (LCZ696), a supramolecular sodium salt complex of the
neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan …

Background: To investigate the efficacy and safety of sacubitril-valsartan in patients with
heart failure, relevant randomized clinical trials (RCTs) were analyzed. Methods: We used …

Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is
an area of active research. This article is aimed to give an update on recent advances in all …

Purpose Sacubitril/valsartan is a mainstay of the treatment of heart failure with reduced
ejection fraction (HFrEF); however, its effects on exercise performance yielded conflicting …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Abstract Aims The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan
against active controls given renin–angiotensin system inhibitors (RASi) are ethically …

Aims The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Background: The net clinical benefit of cardiac disease-modifying drugs might be influenced
by the interaction of different domains of disease burden. We assessed the relative …

Conclusion Although the totality of scientific evidence supports sacubitril/valsartan as having
incremental efficacy over valsartan in a broad population of patients with HF and EF> 40 …

We conducted a systematic review and meta-analysis to assess all-cause mortality and
heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF …